公开(公告)号：US20220135570A1

公开(公告)日：2022-05-05

申请号：US17500140

申请日：2021-10-13

申请人： Incyte Corporation

发明人： Xiaozhao Wang ,  Peter Niels Carlsen ,  Pei Gan ,  Gia Hoang ,  Yong Li ,  Chao Qi ,  Liangxing Wu ,  Wenqing Yao ,  Zhiyong Yu ,  Wenyu Zhu

IPC分类号： C07D487/04 ,  C07D519/00

摘要： This application relates to compounds of Formula (I): or pharmaceutically acceptable salts thereof, which modulate the activity of adenosine receptors, such as subtypes A2A and A2B receptors, and are useful in the treatment of diseases related to the activity of adenosine receptors including, for example, cancer, inflammatory diseases, cardiovascular diseases, and neurodegenerative diseases.

公开(公告)号：US20210205311A1

公开(公告)日：2021-07-08

申请号：US17138485

申请日：2020-12-30

申请人： Incyte Corporation

发明人： Hui Wang ,  Juan Carlos Almagro ,  Rebecca A. Buonpane ,  Peter Niels Carlsen ,  Taisheng Huang ,  Yong Li ,  Luping Lin ,  Horacio G. Nastri ,  Chao Qi ,  Shaun M. Stewart ,  Pramod Unnikrishnan Thekkat ,  Xiaozhao Wang ,  Liangxing Wu ,  Wenqing Yao ,  Jing Zhou ,  Wenyu Zhu

IPC分类号： A61K31/519 ,  A61K39/395 ,  A61P35/00 ,  A61K31/501 ,  A61K31/506 ,  A61K31/4985 ,  A61K31/444

摘要： The present application provides methods of treating cancer using a combination of an inhibitor of A2A and/or A2B and an inhibitor of PD-1 and/or PD-L1.

公开(公告)号：US20200031835A1

公开(公告)日：2020-01-30

申请号：US16502826

申请日：2019-07-03

申请人： Incyte Corporation

发明人： Xiaozhao Wang ,  Peter Niels Carlsen ,  Pei Gan ,  Gia Hoang ,  Yong Li ,  Chao Qi ,  Liangxing Wu ,  Wenqing Yao ,  Zhiyong Yu ,  Wenyu Zhu

IPC分类号： C07D487/04 ,  C07D519/00

摘要： This application relates to compounds of Formula (I): or pharmaceutically acceptable salts thereof, which modulate the activity of adenosine receptors, such as subtypes A2A and A2B receptors, and are useful in the treatment of diseases related to the activity of adenosine receptors including, for example, cancer, inflammatory diseases, cardiovascular diseases, and neurodegenerative diseases.

公开(公告)号：US12060433B2

公开(公告)日：2024-08-13

申请号：US17138306

申请日：2020-12-30

申请人： Incyte Corporation

发明人： Horacio G. Nastri ,  Shaun M. Stewart ,  Juan Carlos Almagro ,  Jing Zhou ,  Rebecca A. Buonpane ,  Hui Wang ,  Yingnan Chen ,  Xiaozhao Wang ,  Peter Niels Carlsen ,  Yong Li ,  Chao Qi ,  Liangxing Wu ,  Wenqing Yao ,  Wenyu Zhu ,  Taisheng Huang

IPC分类号： C07K16/28 ,  A61K31/135 ,  A61K31/4985 ,  A61P35/00 ,  A61K39/00

CPC分类号： C07K16/2896 ,  A61K31/135 ,  A61K31/4985 ,  A61P35/00 ,  A61K2039/505

摘要： Disclosed are combination therapies comprising administration of a CD73 inhibitor and an adenosine A2A or A2B receptor inhibitor. The disclosed combination therapies are useful in the treatment of diseases related to the activity of adenosine receptors and/or CD73 including, for example, cancer, inflammatory diseases, cardiovascular diseases, and neurodegenerative diseases. Anti-CD73 antibodies and A2A/A2B inhibitors are also disclosed.

公开(公告)号：US20230226040A1

公开(公告)日：2023-07-20

申请号：US17991482

申请日：2022-11-21

申请人： Incyte Corporation

发明人： Alejandro Amador Arjona ,  Angela Abdollahi ,  Margaret Favata ,  Jonathan Rios-Doria ,  Hui Wang ,  Susan Wee ,  Pei Gan ,  Jeffrey C. Yang ,  Yong Li ,  Le Zhao ,  Chunhong He ,  Chunyin Marshall Law ,  Wenyu Zhu ,  Xiaozhao Wang ,  Wenqing Yao ,  Peter Niels Carlsen ,  Fenglei Zhang ,  Qinda Ye ,  Matthew S. McCammant ,  Rocco Policarpo ,  Artem Shvartsbart ,  Jeremy Roach ,  Gia Hoang ,  Bin Hu ,  Gencheng Li ,  Robert Susick ,  Padmaja Polam ,  Chao Qi ,  Alexander Sokolsky ,  Haolin Yin ,  Chang Min

IPC分类号： A61K31/4745 ,  A61P35/00 ,  A61P11/00 ,  A61K31/5377 ,  A61K31/519 ,  A61K31/498 ,  A61K31/506 ,  A61K45/06

CPC分类号： A61K31/4745 ,  A61P35/00 ,  A61P11/00 ,  A61K31/5377 ,  A61K31/519 ,  A61K31/498 ,  A61K31/506 ,  A61K45/06

摘要： The present disclosure relates to methods of treating cancer by administering a compound, which is a Fibroblast Growth Factor Receptor (FGFR) inhibitor, in combination with a Kirsten rat sarcoma (KRAS) inhibitor.

公开(公告)号：US20210230294A1

公开(公告)日：2021-07-29

申请号：US17138306

申请日：2020-12-30

申请人： Incyte Corporation

发明人： Horacio G. Nastri ,  Shaun M. Stewart ,  Juan Carlos Almagro ,  Jing Zhou ,  Rebecca A. Buonpane ,  Hui Wang ,  Yingnan Chen ,  Xiaozhao Wang ,  Peter Niels Carlsen ,  Yong Li ,  Chao Qi ,  Liangxing Wu ,  Wenqing Yao ,  Wenyu Zhu ,  Taisheng Huang

IPC分类号： C07K16/28 ,  A61P35/00 ,  A61K31/135 ,  A61K31/4985

摘要： Disclosed are combination therapies comprising administration of a CD73 inhibitor and an adenosine A2A or A2B receptor inhibitor. The disclosed combination therapies are useful in the treatment of diseases related to the activity of adenosine receptors and/or CD73 including, for example, cancer, inflammatory diseases, cardiovascular diseases, and neurodegenerative diseases. Anti-CD73 antibodies and A2A/A2B inhibitors are also disclosed.

公开(公告)号：US11220510B2

公开(公告)日：2022-01-11

申请号：US16377793

申请日：2019-04-08

申请人： Incyte Corporation

发明人： Xiaozhao Wang ,  Peter Niels Carlsen ,  Chunhong He ,  Taisheng Huang

IPC分类号： C07D487/14

摘要： This application relates to compounds of Formula (I): or pharmaceutically acceptable salts or stereoisomers thereof, which modulate the activity of adenosine receptors, such as subtypes A2A and A2B receptors, and are useful in the treatment of diseases related to the activity of adenosine receptors including, for example, cancer, inflammatory diseases, cardiovascular diseases, and neurodegenerative diseases.

公开(公告)号：US20190337957A1

公开(公告)日：2019-11-07

申请号：US16377793

申请日：2019-04-08

申请人： Incyte Corporation

发明人： Xiaozhao Wang ,  Peter Niels Carlsen ,  Chunhong He ,  Taisheng Huang

IPC分类号： C07D487/14

摘要： This application relates to compounds of Formula (I): or pharmaceutically acceptable salts or stereoisomers thereof, which modulate the activity of adenosine receptors, such as subtypes A2A and A2B receptors, and are useful in the treatment of diseases related to the activity of adenosine receptors including, for example, cancer, inflammatory diseases, cardiovascular diseases, and neurodegenerative diseases.

公开(公告)号：US20240360140A1

公开(公告)日：2024-10-31

申请号：US18620225

申请日：2024-03-28

申请人： Incyte Corporation

发明人： Xiaozhao Wang ,  Peter Niels Carlsen ,  Pei Gan ,  Gia Hoang ,  Yong Li ,  Chao Qi ,  Liangxing Wu ,  Wenqing Yao ,  Zhiyong Yu ,  Wenyu Zhu

IPC分类号： C07D487/04 ,  C07D519/00

CPC分类号： C07D487/04 ,  C07D519/00

摘要： This application relates to compounds of Formula (I):




or pharmaceutically acceptable salts thereof, which modulate the activity of adenosine receptors, such as subtypes A2A and A2B receptors, and are useful in the treatment of diseases related to the activity of adenosine receptors including, for example, cancer, inflammatory diseases, cardiovascular diseases, and neurodegenerative diseases.

公开(公告)号：US11999740B2

公开(公告)日：2024-06-04

申请号：US17500140

申请日：2021-10-13

申请人： Incyte Corporation

发明人： Xiaozhao Wang ,  Peter Niels Carlsen ,  Pei Gan ,  Gia Hoang ,  Yong Li ,  Chao Qi ,  Liangxing Wu ,  Wenqing Yao ,  Wenyu Zhu

IPC分类号： A61P9/00 ,  A61K31/4985 ,  A61P3/10 ,  A61P9/10 ,  A61P25/28 ,  A61P29/00 ,  A61P35/00 ,  C07D487/04 ,  C07D519/00

CPC分类号： C07D487/04 ,  C07D519/00

摘要： This application relates to compounds of Formula (I):




or pharmaceutically acceptable salts thereof, which modulate the activity of adenosine receptors, such as subtypes A2A and A2B receptors, and are useful in the treatment of diseases related to the activity of adenosine receptors including, for example, cancer, inflammatory diseases, cardiovascular diseases, and neurodegenerative diseases.